Evidence map›Paper›PMID 34631141›Full record

ReviewObesity science & practice2021

Measuring ketone bodies for the monitoring of pathologic and therapeutic ketosis.

Joseph C Anderson, Samer G Mattar, Frank L Greenway, Richard J Lindquist

2 registry-linked trialsOpen access · goldAbstract readReview
In one paragraph

Review in Obesity science & practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05225467 completednot on this mapstarted 2022, after this paper: background citation

Development of Ketoacidosis During the Perioperative Period: an Observational Study 'The DKAP Study'

Typeobservational_patient_registrySponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Ran2022 to 2023Enrolled58ConditionsKetosis, Keto Acidosis, Ketoses, Metabolic, Ketosis, Diabetic
NCT05469997 nacompletednot on this mapstarted 2023, after this paper: background citation

Ketogenic Diet Interventions in Parkinson's Disease: Safeguarding the Gut Microbiome

TypeinterventionalSponsorUniversity of British ColumbiaRan2023 to 2024Enrolled52ConditionsParkinson DiseaseArmsMediterranean-Ketogenic Diet, Mediterranean diet supplemented with medium-chain triglyceride oil
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Nanowire Array Breath Acetone Sensor for Diabetes Monitoring.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Joseph C AndersonDepartment of Bioengineering University of Washington Seattle Washington USA.ORCID https://orcid.org/0000-0003-4030-8897
Samer G MattarDepartment of Surgery Baylor College of Medicine Houston Texas USA.
Frank L GreenwayPennington Biomedical Research Center Baton Rouge Louisiana USA.
Richard J LindquistDepartment of Family Medicine Swedish Medical Center Seattle Washington USA.
Baylor College of Medicine · USPennington Biomedical Research Center · USSwedish Medical Center · USUniversity of Washington · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

backgroundThe ketone bodies β-hydroxybutyrate (BOHB) and acetone are generated as a byproduct of the fat metabolism process. In healthy individuals, ketone body levels are ∼0.1 mM for BOHB and ∼1 part per million for breath acetone (BrAce). These levels can increase dramatically as a consequence of a disease process or when used therapeutically for disease treatment. For example, increased ketone body concentration during weight loss is an indication of elevated fat metabolism. Ketone body measurement is relatively inexpensive and can provide metabolic insights to help guide disease management and optimize weight loss.

methodsThis review of the literature provides metabolic mechanisms and typical concentration ranges of ketone bodies, which can give new insights into these conditions and rationale for measuring ketone bodies.

resultsDiseases such as heart failure and ketoacidosis can affect caloric intake and macronutrient management, which can elevate BOHB 30-fold and BrAce 1000-fold. Other diseases associated with obesity, such as brain dysfunction, cancer, and diabetes, may cause dysfunction because of an inability to use glucose, excessive reliance on glucose, or poor insulin signaling. Elevating ketone body concentrations (e.g., nutritional ketosis) may improve these conditions by forcing utilization of ketone bodies, in place of glucose, for fuel. During weight loss, monitoring ketone body concentration can demonstrate program compliance and can be used to optimize the weight-loss plan.

conclusionsThe role of ketone bodies in states of pathologic and therapeutic ketosis indicates that accurate measurement and monitoring of BOHB or BrAce will likely improve disease management. Bariatric surgery is examined as a case study for monitoring both types of ketosis.

Indexed as

acetonebariatric surgerymetabolismβ‐hydroxybutyrate

Identifiers

PMID34631141
PMCPMC8488448
OpenAlexW3158967515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.